Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases.
Adolescent
Adult
Aged
Aged, 80 and over
Child
Child, Preschool
Databases, Factual
/ statistics & numerical data
Diagnosis, Differential
Doxycycline
/ adverse effects
Drug Monitoring
/ statistics & numerical data
Enoxaparin
/ adverse effects
Female
France
/ epidemiology
Humans
Linear IgA Bullous Dermatosis
/ chemically induced
Male
Middle Aged
Minocycline
/ adverse effects
Pharmacovigilance
Prevalence
Retrospective Studies
Severity of Illness Index
Stevens-Johnson Syndrome
/ diagnosis
Vancomycin
/ adverse effects
Young Adult
IgA bullous dermatosis
drug reaction
imputability
linear IgA bullous dermatosis
pharmacovigilance
vancomycin
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
11
09
2018
revised:
08
11
2018
accepted:
23
11
2018
pubmed:
5
12
2018
medline:
8
2
2020
entrez:
5
12
2018
Statut:
ppublish
Résumé
Linear immunoglobin A (IgA) bullous dermatosis is a rare autoimmune dermatosis considered spontaneous or drug-induced (DILAD). We assessed all DILAD cases, determined the imputability score of drugs and highlighted suspected drugs. Data for patients with DILAD were collected retrospectively from the French Pharmacovigilance network (from 1985 to 2017) and from physicians involved in the Bullous Diseases French Study Group and the French Investigators for Skin Adverse Reactions to Drugs. Drug causality was systematically determined by the French imputability method. Of the 69 patients, 42% had mucous membrane involvement, 20% lesions mimicking toxic epidermal necrolysis (TEN), 21% eosinophil infiltrates and 10% keratinocytes necrosis. Direct immunofluorescence, in 80%, showed isolated linear IgA deposits. Vancomycin (VCM) was suspected in 39 cases (57%), 11 had TEN-like lesions, as compared with three without VCM suspected. Among the 33 patients with a single suspected drug, 85% had an intrinsic imputability score of I4. Among them, enoxaparin, minocycline and vibramycin were previously unpublished. For all patients, the suspect drug was withdrawn; 15 did not receive any treatment. First-line therapy for 31 patients was topical steroids. Among the 60 patients with available follow-up, 52 achieved remission, 10 without treatment. Four patients experienced relapse, four died and five had positive accidental rechallenges. There is no major clinical difference between DILAD and idiopathic linear IgA bullous dermatosis, but the former features a higher prevalence of patients mimicking TEN. VCM, suspected in more than half of the cases, might be responsible for more severe clinical presentations. We report three new putative drugs.
Identifiants
pubmed: 30511379
doi: 10.1111/bcp.13827
pmc: PMC6379232
doi:
Substances chimiques
Enoxaparin
0
Vancomycin
6Q205EH1VU
Minocycline
FYY3R43WGO
Doxycycline
N12000U13O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
570-579Informations de copyright
© 2018 The British Pharmacological Society.
Références
J Am Acad Dermatol. 2012 Jun;66(6):988-94
pubmed: 22169257
Ann Dermatol Venereol. 2011 Mar;138(3):214-20
pubmed: 21397151
J Clin Invest. 1990 Mar;85(3):812-20
pubmed: 2107211
Clin Dermatol. 1991 Jul-Sep;9(3):383-92
pubmed: 1806226
Therapie. 1985 Mar-Apr;40(2):111-8
pubmed: 4002188
Br J Dermatol. 2014 Dec;171(6):1602-4
pubmed: 24909099
Br J Clin Pharmacol. 2019 Mar;85(3):570-579
pubmed: 30511379
Dermatology. 2013;227(3):209-13
pubmed: 24135381
Ann Dermatol Venereol. 1993;120(11):847-8
pubmed: 8210142
J Invest Dermatol. 2019 Apr;139(4):835-841
pubmed: 30543900
J Am Acad Dermatol. 2018 Jun;78(6):1090-1096
pubmed: 29274348
J Dermatol. 2008 Nov;35(11):737-43
pubmed: 19120770
Australas J Dermatol. 2001 Aug;42(3):196-9
pubmed: 11488715
J Am Acad Dermatol. 1994 Feb;30(2 Pt 1):187-92
pubmed: 7904616
Br J Dermatol. 2010 Apr;162(4):743-50
pubmed: 19886889
Br J Dermatol. 2014 Nov;171(5):1248-53
pubmed: 24684224
Mayo Clin Proc. 2000 Sep;75(9):967-70
pubmed: 10994833
Br J Dermatol. 2013 Nov;169(5):1041-8
pubmed: 23815152
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
J Eur Acad Dermatol Venereol. 2008 Sep;22(9):1131
pubmed: 18221336
Br J Dermatol. 2017 Jul;177(1):212-222
pubmed: 27995619
Acta Derm Venereol. 1981;61(5):439-41
pubmed: 6172936
J Am Acad Dermatol. 2000 Feb;42(2 Pt 2):316-23
pubmed: 10640923
Ann Dermatol Venereol. 2011;138(4):302-6
pubmed: 21497257
Clin Exp Dermatol. 2017 Apr;42(3):299-302
pubmed: 28084616
Br J Dermatol. 1997 Mar;136(3):406-11
pubmed: 9115927
J Invest Dermatol. 2018 Jul;138(7):1473-1480
pubmed: 29410066
J Am Acad Dermatol. 2010 May;62(5):897-8
pubmed: 20398825
Therapie. 2013 Mar-Apr;68(2):69-76
pubmed: 23773347
Arch Dermatol. 1976 Jun;112(6):837-8
pubmed: 782363
Int J Dermatol. 2009 Sep;48(9):1006-10
pubmed: 19702992
Br J Dermatol. 2013 Jul;169(1):210-1
pubmed: 23448154
Dermatology. 1999;199(1):25-30
pubmed: 10449953
Acta Derm Venereol. 2015 Apr;95(4):466-71
pubmed: 25350667